IMTE unhaled down finally BUT BOXL unhalted to upside & halted again so fingers crossed on this one!!
Still in BOXL ($7.25) & is halted to upside again & probably should get greedy but maybe it will do an IMTE lol
AMDA made a nice run, seems to have more left in it considering an after hours spike.... this will be close radar for tomorrow. Additionally, CRSP had hell of a day...I'm just not sure where its headed from here.
Need more folks to play with here for sure but nice to see you here b/c looks like @Neil Allen is MIA with B Russ Congrats on AMDA - nice catalyst but i only got 1 little scalp today but will be watching in morning & hope 3 day rule will apply here!! did another IMGN short & should have picked up some @ low today to play back up but think i might get another chance. Couple swings >> SAGE - RDFN doing pretty well so far & watching a few others already on this board.
"Declares dividend of $0.4220 per Class A common share for second quarter 2018 -" And growth by 5.5% to the moment. How does it work? Anyone who bought it beforehand, what was your thinking?
Thurs. 5/10: AVEO: $2.22 - (9) insider buys of 71,000 @ $2.13 shares posted 5pm. New oncology med approved in Europe - waiting for results of Phase 3 trials. AVEO Aveo Pharmaceuticals Inc - posted 5/10/18 Barris Peter J: Buy 70,873 shares $2.13 $151,242 17:00:43 Baskett Forest (10% Owner) Buy 70,873 $2.13 $151,242 17:01:06 Florence Anthony A. Jr. (10% Owner) Buy 70,873 $2.13 $151,242 17:01:28 Makower Joshua (10% Owner) Buy 70,873 $2.13 $151,242 17:01:52 Mott David M (10% Owner) Buy 70,873 $2.13 $151,242 17:02:15 Sakoda Jon (10% Owner) Buy 70,873 $2.13 $151,242 17:02:40 Sandell Scott D (10% Owner) Buy 70,873 $2.13 $151,242 17:03:03 Sonsini Peter W. (10% Owner) Buy 70,873 $2.13 $151,242 17:03:28 Viswanathan Ravi (10% Owner) Buy 70,873 $2.13 $151,242 17:03:51
definitely has come down since first post but still on radar, especially with the massive amount of insider buying that has been going on - think this one is gonna be real good when it gets going & came close to scaling in yesterday but decided to wait until friday. and hey - bout time you showed back up Don't remember if posted VTVT in past but swing paid this morning & still on watch for gap fill.
My 2 plays today RDFN which i'm done with but still playing HEAR & watching now for maybe another play - has a gap up there. Adding - welcome Alf
WB earnings: Weibo (WB) reported Q1 EPS of $0.50, $0.03 better than the analyst estimate of $0.47. Revenue for the quarter came in at $349.9 million versus the consensus estimate of $342.39 million. First Quarter 2018 Highlights Net revenues totaled $349.9 million, an increase of 76% year-over-year, exceeding the Company's guidance between $335 million and $345 million. Advertising and marketing revenues were $302.9 million, an increase of 79% year-over-year. Value-added service ("VAS") revenues were $46.9 million, an increase of 57% year-over-year. Net income attributable to Weibo was $99.1 million, an increase of 111% year-over-year, and diluted net income per share was $0.44, compared to $0.21 for the same period last year. Non-GAAP net income attributable to Weibo was $112.6 million, an increase of 95% year-over-year, and non-GAAP diluted net income per share was $0.50, compared to $0.26 for the same period last year. Adjusted EBITDA was $124.6 million, an increase of 77% year-over-year, or 36% of net revenues, compared to 35% for the same period last year. Monthly active users ("MAUs") had a net addition of approximately 70 million users year over year and reached 411 million in March 2018. Mobile MAUs represented 93% of MAUs. Average daily active users ("DAUs") had a net addition of approximately 30 million users year over year and reached 184 million in March 2018.
AVEO: $2.17 - "29 HEDGE FDS BUY AVEO FOR THE FIRST TIME" May 9, 2018 AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has made a 290.35% comeback from a 12-month low price of $0.57. It was seen -9.92% lower, changing the price to $2.22, when the closing bell rang on 05/08/2018. At recent session, the prices were hovering between $2.05 and $2.319. This company shares are 155.41% off its target price of $5.67 and the current market capitalization stands at $263.57M. The recent change has given its price a -18.37% deficit over SMA 50 and -47.52% deficit over its 52-week high. The stock witnessed -11% declines, -27.29% declines and -30.69% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVEO’s volatility during a week at 7.38% and during a month it has been found around 5.75%. AVEO Pharmaceuticals, Inc. (AVEO) Top Holders Institutional investors currently hold around $152 million or 53.3% in AVEO stock. Look at its top three institutional owners. Nea Management Company, Llc owns $40.42 million in AVEO Pharmaceuticals, Inc., which represents roughly 15.33% of the company’s market cap and approximately 26.59% of the institutional ownership. Similar statistics are true for the second largest owner, Polar Capital Llp, which owns 8,077,429 shares of the stock are valued at $19.95 million. The third largest holder is Ra Capital Management, Llc, which currently holds $12.51 million worth of this stock and that ownership represents nearly 4.74% of its market capitalization. AVEO Pharmaceuticals, Inc. 13F Filings At the end of 12/31/2017 reporting period, 51 institutional holders increased their position in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by some 11,128,085 shares, 25 decreased positions by 10,336,256 and 15 held positions by 39,899,750. That puts total institutional holdings at 61,364,091 shares, according to SEC filings. The stock grabbed 29 new institutional investments totaling 5,601,760 shares while 10 institutional investors sold out their entire positions totaling 988,027 shares. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Insider Trades Multiple company employees have indulged in significant insider trading. AVEO Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Growth Equity Opportunities Iv has acquired 920,976 shares of AVEO Pharmaceuticals, Inc. (AVEO) in trading session dated Apr. 10, 2018. These shares are worth $2,118,245 and were traded at $2.3 each. The SEC filing shows that Barris Peter J performed a purchase of 920,976 shares. The 10% Owner added these shares by way of transaction on Apr. 10, 2018. The company’s shares were assimilated at $2.3 per share worth to an investment of some $2,118,245 on account of Barris Peter J. 10% Owner, Baskett Forest, purchased 920,976 common shares of AVEO Pharmaceuticals, Inc. (AVEO) in the open market. In a transaction dated Apr. 10, 2018, the shares were bought at an average price of $2.3, giving away a sum of $2,118,245. After this purchase, 17,283,670 common shares of AVEO are directly owned by the insider, with total stake valued at $38,369,747. In the transaction dated Apr. 10, 2018, the great number of shares acquired came courtesy the 10% Owner; Florence Anthony A. Jr. added a total of 920,976 shares at an average price of $2.3, amounting to approximately $2,118,245. The insider now directly owns 17,283,670 shares worth $38,369,747. AVEO Pharmaceuticals, Inc. (AVEO) Analyst Guide Several analysts have released their opinion on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.
Fireopal be callin me out! Kinda flattering actually, since i rarely offer anything good to analyse. Well i will be playing again no later than monday i mean next monday not tomorrow but i will def try to get in here and prep for plays all week. Glad to see you are keeping it alive here.
don't know if you saw but catching up on some reading with a few picks that seem to be on my 4ever stock watch list & read your article along with one hedge fund, Leaf something or another reducing stake + results pushed up to Q3 now so good chance of getting some closer to $2 or a bit lower. "...Tivozanib TIVO-3 Study North America Update Update on Anticipated Timeline to Topline Data from Phase 3 TIVO-3 Study. AVEO today announced that the pre-specified number of progression free survival (PFS) events required to trigger data analysis of the Phase 3 TIVO-3 trial have not been reached at this time and, as such, the Company is amending its guidance for the anticipated topline data readout from the second to the third quarter of 2018. In collaboration with the CRO conducting the TIVO-3 study, AVEO has taken measures to shorten the data cleaning and analysis period following the pre-specified events trigger from 8-10 weeks down to 6-8 weeks. Together with the previously completed TIVO-1 trial of tivozanib in the first line treatment of aRCC, TIVO-3 is designed to support regulatory approval of tivozanib in the U.S. as a first- and third-line treatment for aRCC..."
